Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129241 | 0.86 | RAB9A (0.34) | RAB9A | |
| SCHEMBL441487 | 0.84 | RAB9A (0.54) | RAB9ALMNA | |
| SCHEMBL27014888 | 0.83 | RAB9A (0.44) | RAB9ALMNA | |
| SCHEMBL25051819 | 0.82 | RAB9A (0.32) | RAB9A | |
| SCHEMBL19523554 | 0.78 | — | — | |
| SCHEMBL19544704 | 0.76 | RAB9A (0.34) | RAB9A | |
| SCHEMBL10232882 | 0.76 | RAB9A (0.47) | RAB9ALMNA | |
| SCHEMBL19263177 | 0.75 | RAB9A (0.50) | RAB9ALMNA | |
| SCHEMBL4569231 | 0.72 | RAB9A (0.38) | RAB9A | |
| SCHEMBL24624843 | 0.70 | RAB9A (0.55) | RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | VIIV HEALTHCARE COMPANY | 2023-02-09 | — | — | US | disclosed |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-30 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1395/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1395/4885 |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | RAB9A 3126/4885LMNA 2246/4885 |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | RAB9A 1593/4885LMNA 2625/4885 |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | RAB9A 1593/4885LMNA 2625/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1384/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1395/4885 |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | RAB9A 1593/4885LMNA 2625/4885 |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | RAB9A 3126/4885LMNA 2246/4885 |
| US-10723733-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | RAB9A 1809/4885LMNA 2852/4885 |
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1395/4885 |
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | CCR5, SAMHD1, THPO | RAB9A 1796/4885LMNA 4555/4885 |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | RAB9A 1593/4885LMNA 2625/4885 |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | RAB9A 1028/4885LMNA 1395/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | RAB9A 1034/4885LMNA 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.